A Phase 3 Study to Evaluate the Efficacy and Safety of Docetaxel and Prednisone With or Without Lenalidomide in Subjects With Castrate-Resistant Prostate Cancer (CRPC)
Phase of Trial: Phase III
Latest Information Update: 03 May 2017
At a glance
- Drugs Lenalidomide (Primary) ; Docetaxel; Prednisone
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms MAINSAIL
- Sponsors Celgene Corporation
- 05 Apr 2017 Status changed from active, no longer recruiting to completed.
- 09 Mar 2017 This trial has been completed in Greece (end date: 28 Nov 2016).
- 03 Feb 2017 This trial has been completed in Austria (end date: 28 Nov 2016).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History